|
Jack W. Singer, M.D. is a founder and Director of CTI and was appointed Chief Medical Officer in January 2004. Dr. Singer was formerly Executive Vice President, Research Program Chair. As Chief Medical Officer, Dr. Singer is the primary thought leader for CTI clinical and medical strategy. He is a noted expert in hematologic cancers, having developed the clonal theory of leukemia. He has authored more than 240 peer-reviewed manuscripts and 13 chapters in textbooks on cell biology and clinical drug development and holds 14 patents. He has been an invited speaker at numerous medical conferences, including, the 6th International Symposium on Polymer Therapeutics, and he is a member of the Society for Clinical Investigation.
Prior to joining CTI, Dr. Singer was Professor of Medicine at the University of Washington and full Member of the Fred Hutchinson Cancer Research Center. From 1975 to 1992, he was the Chief of Medical Oncology at the Veterans Administration Medical Center in Seattle. In addition, Singer served as an advisor to the National Cancer Institute and was a consultant to several pharmaceutical companies prior to joining CTI.
| 